Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase 1 study patients with fgfr genomically activated advanced biliary tract cancer

Presented at Gastrointestinal Cancers Symposium 2018, San Francisco, CA, USA

James M. Cleary (1), Martin H. Voss (2), Funda Meric-Bernstam (3), Cinta Hierro (4), Rebecca Suk Heist (5), Nobuya Ishii (6), Yulia Kirpicheva (7), Valérie Nicolas-Metral (7), Anna Pokorska-Bocci (7), Anne Vaslin (7), Youyou Hu (7), Claudio Zanna (7), Keith Flaherty (5), Josep Tabernero (4), Jose Baselga (2)

 

1. Dana-Farber Cancer Institute, Boston, MA;
2. Memorial Sloan-Kettering Cancer Center, New York, NY;
3. The University of Texas MD Anderson Cancer Center, Houston, TX;
4. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
5. Massachusetts General Hospital Cancer Center, Boston, MA;
6. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan;
7. Debiopharm International SA, Lausanne, Switzerland